Skip to main
MTSR
MTSR logo

Metsera Inc (MTSR) Stock Forecast & Price Target

Metsera Inc (MTSR) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Metsera Inc is positioned favorably within the biotechnology sector due to its development of next-generation injectable and oral nutrient-stimulated hormone analog peptides, which have the potential to outpace existing therapies in addressing obesity and related conditions. The company's proprietary technologies, including the MINT peptide library and the Half-life Augmentation by Lipid Optimization platform, enhance the efficacy and safety of its products by promoting sustained activity through selective biased agonists that do not activate β-arrestin. Promising preliminary results from clinical trials, including a placebo-adjusted weight loss of 14% in MET-097i, support confidence in the potential for successful outcomes in future trials, enhancing investor optimism for the company's stock.

Bears say

Metsera Inc. faces significant challenges due to the reduced potency of its lead candidates, TZP and MET-097i, which exhibit approximately one log lower potency than native GLP-1, potentially limiting their efficacy in comparison to competitors. The recent performance of Roche's CT-388, while showing a 19% placebo-adjusted improvement by week 24, highlights the risks associated with rapid titration and poor tolerability, underscoring the competitive hurdles Metsera must overcome. Additionally, the inherent risks associated with small and mid-cap biotechnology companies further amplify concerns about Metsera's financial stability and future market position.

Metsera Inc (MTSR) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Metsera Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Metsera Inc (MTSR) Forecast

Analysts have given Metsera Inc (MTSR) a Buy based on their latest research and market trends.

According to 4 analysts, Metsera Inc (MTSR) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $58.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $58.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Metsera Inc (MTSR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.